Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Development of a compact anti-BAFF antibody in Escherichia coli

Abstract

Recombinant antibodies, especially single-chain antibody fragment (scFv), can be applied as detection reagents and even substitute for some reagents used in immunoassays. For scFv fragments, there is no such universal system available up to now. We have constructed vectors for the convenient, rapid expression of a novel compact antibody composed of anti-B-cell-activating factor of the TNF family (BAFF) scFv and the Fc portion (the hinge region, CH2, and CH3 domains) of the human IgG1 in Escherichiacoli. After expression in bacteria as inclusion bodies, the recombinant antibody was purified and refolded in vitro. The scFv-Fc antibody was demonstrated to retain high binding affinity to antigen, including membrane-bound BAFF and soluble BAFF, and to possess some human IgG crystallizable fragment domain functions, such as human complement C1q and protein A binding. Both size-exclusion high-performance liquid chromatography column analysis and Western blotting of proteins subjected to nonreducing sodium dodecyl sulfate polyacrylamide gel electrophoresis suggested that scFv-Fc antibody is homodimeric with relative molecular mass of 110 kDa. These findings suggest that the compact antibody may be useful in diagnostic application for the prediction of BAFF relevant to autoimmune diseases in human.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

References

  1. Adams GP, McCartney JE, Tai MS, Oppermann H, Huston JS, Stafford WF, Bookman MA, Fand I, Houston LL, Weiner LM (1993) Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv. Cancer Res 53:4026–4034

  2. Baker KP, Edwards BM, Main SH, Choi GH, Wager RE, Halpern WG, Lappin PB, Riccobene T, Abramian D, Sekut L, Sturm B, Poortman C, Minter RR, Dobson CL, Williams E, Carmen S, Smith R, Roschke V, Hilbert DM, Vaughan TJ, Albert VR (2003) Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. 48:3253–3265

  3. Borsi L, Balza E, Bestagno M, Castellani P, Carnemolla B, Biro A, Leprini A, Sepulveda J, Burrone O, Neri D, Zardi L (2002) Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int J Cancer 102:75–85

  4. Burton DR (1985) Immunoglobulin G: functional sites. Mol Immunol 22:161–206

  5. Cao P, Xia Z, Song W, Zhang S (2005a) Neutralizing human anti-B-cell-activating factor of the TNF family (BAFF) scFv selected from phage antibody library. Immunol Lett 101:87–94

  6. Cao P, Mei JJ, Diao ZY, Zhang SQ (2005b) Expression, refolding, and characterization of human soluble BAFF synthesized in Escherichiacoli. Protein Expr Purif 41:199–206

  7. Cao P, Tang XM, Guan ZB, Diao ZY, Zhang SQ (2005c) Production and characterization of a bacterial single-chain antibody fragment specific to B-cell-activating factor of the TNF family. Protein Expr Purif 43:157–164

  8. Laemmli UK (1970) Cleavage of structural proteins during assembly of the heat of bacteriophage T4. Nature 277:680–685

  9. Isenman DE, Dorrington KJ, Painter RH (1975) The structure and function of immunoglobulin domains. II. The importance of interchain disulfide bonds and the possible role of molecular flexibility in the interaction between immunoglobulin G and complement. J Immunol 114:1726–1729

  10. Mackay F, Browning JL (2002) BAFF: a fundamental survival factor for B cells. Nat Rev Immunol 2:465–475

  11. Melchers F (2003) Actions of BAFF in B cell maturation and its effects on the development of autoimmune disease. Ann Rheum Dis 62:225–227

  12. Milenic DE, Yokota T, Filpula DR, Finkelman MA, Dodd SW, Wood JF, Whitlow M, Snoy P, Schlom J (1991) Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. Cancer Res 51:6363–6371

  13. Moore PA, Belvedere O, Orr A, Pieri K, LaFleur DW, Feng P, Soppet D, Charters M, Gentz R, Parmelee D, Li Y, Galperina O, Giri J, Roschke V, Nardelli B, Carrell J, Sosnovtseva S, Greenfield W, Ruben SM, Olsen HS, Fikes J, Hilbert DM (1999) BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 285:260–263

  14. Mukhopadhyay A, Ni J, Zhai Y, Yu GL, Aggarwal BB (1999) Identification and characterization of a novel cytokine, THANK, a TNF homologue that activates apoptosis, nuclear factor-κB, and c-Jun NH2-terminal kinase. J Biol Chem 274:15978–15981

  15. Nardelli B, Belvedere O, Roschke V, Moore PA, Olsen HS, Migone TS, Sosnovtseva S, Carrell JA, Feng P, Giri JG, Hilbert DM (2001) Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood 97:198–204

  16. Owens RJ, Young RJ (1994) The genetic engineering of monoclonal antibodies. J Immunol Methods 168:149–165

  17. Ramanujam M, Davidson A (2004) The current status of targeting BAFF/BlyS for autoimmune diseases. Arthritis Res Ther 6:197–202

  18. Reff ME, Heard C (2001) A review of modifications to recombinant antibodies: attempt to increase efficacy in oncology applications. Crit Rev Oncol Hematol 40:25–35

  19. Schiemann B, Gommerman JL, Vora K, Cachero TG, Shulga-Morskaya S, Dobles M, Frew E, Scott ML (2001) An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 293:2111–2114

  20. Schneider P, Tschopp J (2003) BAFF and the regulation of B cell survival. Immunol Lett 88:57–62

  21. Schneider P, MacKay F, Steiner V, Hofmann K, Bodmer JL, Holler N, Ambrose C, Lawton P, Bixler S, Acha-Orbea H, Valmori D, Romero P, Werner-Favre C, Zubler RH, Browning JL, Tschopp J (1999) BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 189:1747–1756

  22. Shu HB, Hu WH, Johnson H (1999) TALL-1 is a novel member of the TNF family that is down-regulated by mitogens. J Leukoc Biol 65:680–683

  23. Studier FW (1991) Use of bacteriophage T7 lysozyme to improve an inducible T7 expression system. J Mol Biol 219:37–44

  24. Tribouley C, Wallroth M, Chan V, Paliard X, Fang E, Lamson G, Pot D, Escobedo J, Williams LT (1999) Characterization of a new member of the TNF family expressed on antigen presenting cells. Biol Chem 380:1443–1447

  25. Yokota T, Milenic DE, Whitlow M, Schlom J (1992) Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 52:3402–3408

Download references

Acknowledgements

We thank Dr. Zhinan Xia for many useful discussions during the course of the experiments. This work was supported by the Grants of Nanjing Normal University and Jiansu Province Graduate Innovation Project (No. 1612005013) administered by Dr. Cao.

Author information

Correspondence to Shuangquan Zhang.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Cao, P., Zhang, S., Gong, Z. et al. Development of a compact anti-BAFF antibody in Escherichia coli . Appl Microbiol Biotechnol 73, 151–157 (2006). https://doi.org/10.1007/s00253-006-0432-4

Download citation

Keywords

  • Human IgG1
  • Recombinant Antibody
  • Tumor Necrosis Factor Family
  • Phage Antibody Library
  • T7lac Promoter